948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

Hans Wildiers; Luc Dirix; Anne Armstrong; Eveline De Cuypere; Florence Dalenc; Steven Chan; Frederik Marme; Carolina Pia Schröder; Jens Huober; Peter Vuylsteke; Jean-Philippe Jacquin; Etienne Brain; Sherko Kümmel; Zsuzsanna Pápai; Christian Mueller; Chrystelle Brignone; Frederic Triebel

doi:10.1136/jitc-2021-SITC2021.948

Article info

Late-Breaking Abstracts

Clinical Trials Complete

948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

Free

Authors

Hans Wildiers University Hospitals Leuven; Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven, Belgium PubMed articles Google scholar articles
Luc Dirix GZA Ziekenhuizen campus Sint-Augustin, Oosterveldlaan, Belgium PubMed articles Google scholar articles
Anne Armstrong The Christie NHS Foundation Trust, Manchester, UK PubMed articles Google scholar articles
Eveline De Cuypere AZ Sint-Jan Brugge-Oostende AV, Ruddershove, Belgium PubMed articles Google scholar articles
Florence Dalenc Institut Claudius Regaud (Institut Claudius regaud- Institut Universitaire du Cancer – Oncopole), Toulouse, France PubMed articles Google scholar articles
Steven Chan Nottingham Cancer Clinical Trials Team, Nottingham, UK PubMed articles Google scholar articles
Frederik Marme National Center for Tumor Diseases (NCT), Heidelberg, Germany PubMed articles Google scholar articles
Carolina Pia Schröder University Medical Center Groningen, Groningen, Netherlands PubMed articles Google scholar articles
Jens Huober Universitätsfrauenklinik Ulm, Ulm, Germany PubMed articles Google scholar articles
Peter Vuylsteke CMSE UCLouvain, CHU UCL NAMUR Site Ste-Elisabeth, AND University of Botswana, Uccle, Belgium PubMed articles Google scholar articles
Jean-Philippe Jacquin Institut de Cancérologie de la Loire, Saint Priest en Jarez, France PubMed articles Google scholar articles
Etienne Brain Institut Curie -Hôpital René Huguenin, Saint-Cloud, France PubMed articles Google scholar articles
Sherko Kümmel KEM | Evang. Kliniken Essen-Mitte, Essen, Germany PubMed articles Google scholar articles
Zsuzsanna Pápai MH Egészségügyi Központ Onkológiai, Budapest, Hungary PubMed articles Google scholar articles
Christian Mueller Immutep, Berlin, Germany PubMed articles Google scholar articles
Chrystelle Brignone Immutep, Berlin, Germany PubMed articles Google scholar articles
Frederic Triebel Immutep, Berlin, Germany PubMed articles Google scholar articles

Citation

Wildiers H, Dirix L, Armstrong A, et al

948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.948

Publication history

First published November 10, 2021.

Online issue publication

November 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password